Move Could Derail Biotie Acquisition
Merck Serono Hands Safinamide Back To Newron
By Cormac Sheridan
Monday, October 24, 2011
To say that Timo Veromaa, CEO of Biotie Therapies Oyj, was not best pleased with Merck Serono SA's surprise decision to exit a partnership with Newron Pharmaceuticals SpA on the Parkinson's drug safinamide would be an understatement. The timing of the announcement smack in the middle of Biotie's proposed takeover of Newron "is completely unorthodox," he told BioWorld Today. "To drop the ball right in the middle of [a pivotal Phase III program] is astonishing."
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.